TherapeuticsMD reports second quarter 2026 results, continues strategic review

TherapeuticsMD, Inc. reported financial results for the quarter ended June 30, 2026 in a release dated August 11, 2026. The company now operates as a pharmaceutical royalty holder rather than a commercial drugmaker. TherapeuticsMD was previously a women's healthcare company but changed its business in December 2022 to become a pharmaceutical royalty company that primarily collects royalties from its licensees, and it is no longer engaged in research and development or commercial operations.¹

On the strategic front, the company said it continues to evaluate a variety of strategic alternatives that may include an acquisition, merger, other business combination, sale of assets, or other strategic transactions, though it cautioned there is no assurance of a transaction or of the form or timing of any outcome, and it has not set a timetable for completing this review and does not plan to disclose further developments unless it decides disclosure is appropriate.¹

On the financial side, the company recorded $869 thousand in license revenue for the second quarter of 2026, down from $952 thousand in the second quarter of 2025, a decrease it attributed to changes in sales of licensed products.¹ Net income from continuing operations was $164 thousand, compared with $545 thousand in the second quarter of 2025.¹ Total operating expenses from continuing operations rose to $1.7 million, up $38 thousand or 2.3% from $1.6 million a year earlier, which the company linked mainly to higher general and administrative expenses and a write-off of patents.¹

On liquidity, the company reported cash and cash equivalents of $9.2 million as of June 30, 2026.¹ The filing did not state a specific cash runway figure beyond this balance.